SCHEMBL17152949

SCHEMBL17152949

CC(C)(C)OC(=O)CN1CCN(Cc2cc([N+](=O)[O-])ccc2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.44
▸ KCNJ1 P48048 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.42
▸ LMNA P02545 5/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HTT P42858 3/20 0.41
▸ MTNR1B P49286 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ DRD4 P21917 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17152952 0.86 ALDH1A1 (0.45) CTSBKCNJ1ALDH1A1LMNAKDM4E
SCHEMBL9883952 0.86 ALDH1A1 (0.48) CTSBKCNJ1ALDH1A1LMNAKDM4E
SCHEMBL17152954 0.85 ALDH1A1 (0.43) CTSBKCNJ1ALDH1A1LMNAKDM4E
SCHEMBL17152947 0.84 ALDH1A1 (0.52) CTSBKCNJ1ALDH1A1LMNAKDM4E
SCHEMBL18412514 0.83 L3MBTL1 (0.43) CTSBKCNJ1ALDH1A1LMNAKDM4E
SCHEMBL17155173 0.83 ALDH1A1 (0.43) CTSBKCNJ1ALDH1A1LMNAKDM4E
SCHEMBL17152793 0.82 MTNR1B (0.44) ALDH1A1KDM4EMTNR1BACHEDRD4
SCHEMBL16656263 0.82 KDM4E (0.56) KCNJ1ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL12195291 0.82 KDM4E (0.56) KCNJ1ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL18412518 0.80 HTR1A (0.47) ALDH1A1LMNAKDM4ESMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 — — US disclosed
US-20170022201-A1 MACROCYLIC PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 — — US disclosed
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 — — US disclosed
WO-2015150557-A1 MACROCYLIC PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 — — WO disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES EEF2K, VPS26B, VPS28 CTSB 344/4885KCNJ1 1880/4885ALDH1A1 4293/4885
US-20170022201-A1 MACROCYLIC PYRIDINE DERIVATIVES VPS26B, VPS4B, VPS28 CTSB 201/4885KCNJ1 1427/4885ALDH1A1 4381/4885
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 CTSB 344/4885KCNJ1 1880/4885ALDH1A1 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback